Client Result
Orrick Advises Ipsen on Acquisition of Epizyme
June.27.2022

The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
December.20.2021
May.19.2021
January.29.2021
November.12.2019
November.06.2019
March.11.2019